MindImmune Therapeutics, Inc.

📍 Kingston, United States🗓 Founded 2016👥 13 employees💰 Last funded Nov 2025
Biotechnology Research🌐 mindimmune.com
Website LinkedIn
MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimers disease (AD) as initial clinical indication. The companys lead program is an antibody-based therapeutic, aiming to inhibit an innate immune response originating in the periphery which is triggered by AD pathology. The lead program is in late stage pre-clinical development, contemplating IND filing near-term. If successful in clinical development, the companys therapeutic strategy would represent a fundamental breakthrough for the AD field. MindImmune scientists are at the forefront in recognizing the therapeutic opportunities in targeting the immune system to treat brain disease. MindImmune is based in Kingston, RI and is building an affiliation with the George & Anne Ryan Institute for Neuroscience at the University of Rhode Island to leverage the rapidly expanding Rhode Island ecosystem of academic neurosciences resources to advance its drug development programs.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in MindImmune Therapeutics, Inc.?
MindImmune Therapeutics, Inc. has 1 investors on record on gritt.io and 1 late-stage investors.
When did MindImmune Therapeutics, Inc. last raise funding?
The most recent investment in MindImmune Therapeutics, Inc. recorded on gritt.io was in November 2025.
When was MindImmune Therapeutics, Inc. founded?
MindImmune Therapeutics, Inc. was founded in 2016.
What industry is MindImmune Therapeutics, Inc. in?
MindImmune Therapeutics, Inc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is MindImmune Therapeutics, Inc. based?
MindImmune Therapeutics, Inc. is headquartered in Kingston, United States.